Literature DB >> 14328982

H-1 VIRUS VIREMIA IN THE HUMAN.

H W TOOLAN, E L SAUNDERS, C M SOUTHAM, A E MOORE, A G LEVIN.   

Abstract

Entities:  

Keywords:  BLOOD; GUINEA PIGS; HAMSTERS; HEMAGGLUTINATION; MICROSCOPY, ELECTRON; ONCOGENIC VIRUSES; PAPOVAVIRUS; PATHOLOGY

Mesh：

Year:  1965        PMID： 14328982     DOI： 10.3181/00379727-119-30278

Source DB:  PubMed          Journal:  Proc Soc Exp Biol Med        ISSN： 0037-9727


× No keyword cloud information.
  19 in total

1.  Regression of advanced rat and human gliomas by local or systemic treatment with oncolytic parvovirus H-1 in rat models.

Authors:  Karsten Geletneky; Irina Kiprianova; Ali Ayache; Regina Koch; Marta Herrero Y Calle; Laurent Deleu; Clemens Sommer; Nadja Thomas; Jean Rommelaere; Jörg R Schlehofer
Journal:  Neuro Oncol       Date:  2010-03-18       Impact factor: 12.300

2.  Structural characterization of H-1 parvovirus: comparison of infectious virions to empty capsids.

Authors:  Sujata Halder; Hyun-Joo Nam; Lakshmanan Govindasamy; Michèle Vogel; Christiane Dinsart; Nathalie Salomé; Robert McKenna; Mavis Agbandje-McKenna
Journal:  J Virol       Date:  2013-02-28       Impact factor: 5.103

3.  Neutralization of an infectious herpes simplex virus-antibody complex by anti-gamma-globulin.

Authors:  W K Ashe; A L Notkins
Journal:  Proc Natl Acad Sci U S A       Date:  1966-08       Impact factor: 11.205

Review 4.  Intratumoral Immunotherapy-Update 2019.

Authors:  Omid Hamid; Rubina Ismail; Igor Puzanov
Journal:  Oncologist       Date:  2019-11-29

5.  Use of an autonomous parvovirus vector for selective transfer of a foreign gene into transformed human cells of different tissue origins and its expression therein.

Authors:  F Dupont; L Tenenbaum; L P Guo; P Spegelaere; M Zeicher; J Rommelaere
Journal:  J Virol       Date:  1994-03       Impact factor: 5.103

6.  Phase I/IIa study of intratumoral/intracerebral or intravenous/intracerebral administration of Parvovirus H-1 (ParvOryx) in patients with progressive primary or recurrent glioblastoma multiforme: ParvOryx01 protocol.

Authors:  Karsten Geletneky; Johannes Huesing; Jean Rommelaere; Joerg R Schlehofer; Barbara Leuchs; Michael Dahm; Ottheinz Krebs; Magnus von Knebel Doeberitz; Bernard Huber; Jacek Hajda
Journal:  BMC Cancer       Date:  2012-03-21       Impact factor: 4.430

Review 7.  Oncolytic viruses & their specific targeting to tumour cells.

Authors:  Prafull K Singh; Juwar Doley; G Ravi Kumar; A P Sahoo; Ashok K Tiwari
Journal:  Indian J Med Res       Date:  2012-10       Impact factor: 2.375

Review 8.  Oncolytic immunotherapy: unlocking the potential of viruses to help target cancer.

Authors:  Omid Hamid; Brianna Hoffner; Eduard Gasal; Jenny Hong; Richard D Carvajal
Journal:  Cancer Immunol Immunother       Date:  2017-07-15       Impact factor: 6.968

Review 9.  Tumor Selectivity of Oncolytic Parvoviruses: From in vitro and Animal Models to Cancer Patients.

Authors:  Assia L Angelova; Karsten Geletneky; Jürg P F Nüesch; Jean Rommelaere
Journal:  Front Bioeng Biotechnol       Date:  2015-04-22

10.  Oncosuppressive suicide gene virotherapy "PVH1-yCD/5-FC" for pancreatic peritoneal carcinomatosis treatment: NFκB and Akt/PI3K involvement.

Authors:  Soukaina Réjiba; Christelle Bigand; Celine Parmentier; Ahmed Masmoudi; Amor Hajri
Journal:  PLoS One       Date:  2013-08-14       Impact factor: 3.240
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.